Clinical Trials

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT04892173 2026-03-13

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Phase 3 Recruiting

500 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07435311 2026-02-27

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1 Completed

118 enrolled

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07435324 2026-02-27

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

161 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Phase 1 Recruiting

240 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05249426 2026-01-21

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Phase 1 Active not recruiting

48 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06194656 2026-01-16

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

81 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04428151 2025-12-04

LEAP-009

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

89 enrolled 14 charts

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT05786924 2025-11-20

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase 1/2 Recruiting

554 enrolled

CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

42 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05061420 2025-09-22

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Phase 2 Terminated

59 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck

NCT07059221 2025-07-22

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Phase 1/2 Recruiting

96 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02358031 2025-07-18

MK-3475-048

882 enrolled 50 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04616196 2025-06-08

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

GastrointestinalHead & Neck

25 enrolled 17 charts

Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms

NCT06943820 2025-06-03

AK129 Combination Therapy for Advanced Solid Tumors

Phase 1/2 Recruiting

230 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

DermatologicGenitourinaryHead & NeckThoracic

26 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT02741570 2023-09-21

CheckMate 651

947 enrolled 19 charts

BreastGastrointestinalGynecologicHead & NeckThoracic

Head and Neck Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02499120 2023-09-08

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

125 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02643550 2023-05-12

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

143 enrolled

Head and Neck Neoplasms

NCT03254927 2023-04-03

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Terminated

30 enrolled 17 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05751512 2023-03-02

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Phase 3 Unknown

180 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02627274 2022-11-22

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Phase 1 Completed

134 enrolled

BreastHead & Neck

Breast Neoplasms, Head and Neck Neoplasms

NCT02105636 2022-10-05

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

361 enrolled 14 charts

Phase EARLY_PHASE1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT04065555 2022-07-29

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

12 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02383966 2022-05-13

CHANGE2

243 enrolled 17 charts

Squamous Cell Carcinoma of Head and Neck

NCT01332266 2022-01-03

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

95 enrolled 21 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03319459 2021-11-22

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Phase 1 Completed

44 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02052960 2021-11-02

RESGEX

240 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT02551159 2021-10-13

KESTREL

823 enrolled 23 charts

Squamous Cell Carcinoma of Head and Neck

NCT03349710 2021-08-09

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

74 enrolled 19 charts